CD69 and neoplasm: Besides upregulation of the early activation marker CD69, we report decreased levels of DNAM-1 and increased NKG2A expression on NK cells in coculture with MV-infected tumor cells, which is most pronounced in combination treatments with either tumor-specific MV-BiKE, or MV plus BiKE.